A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase

Shingo Hanaoka1,2 Shinji Saijou1,2 Yasuhiro Matsumura1,2,3

1 RIN Institute Inc., Tokyo, Japan
2 Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
3 Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan

Address for correspondence Yasuhiro Matsumura, MD, PhD, Department of Immune Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan (e-mail: yhmatsum@ncc.go.jp).

Abstract

Tissue plasminogen activator (tPA) is used clinically because it has a higher binding specificity for insoluble fibrin (IF) than urokinase (UK), but even pro-tPA has catalytic activity against substrates other than IF. UK has the advantage that it is specifically activated on IF; however, it binds IF weakly. Previously, we established a monoclonal antibody (mAb) that recognizes a pit structure formed only in IF. Here, we developed a new mAb against the pit, 1101, that does not affect coagulation or fibrinolysis, and prepared a fusion protein of UK with humanized 1101 Fab to transport UK selectively to IF. In IF-containing lesions, UK is cleaved by plasmin at two sites, Lys158/Ile159 and Lys135/Lys136. Cleavage of the former leads to activation of UK; however, because activated UK is linked by S-S bonds before and after cleavage, it is not released from the fusion. Cleavage at the latter site causes UK to leave the fusion protein; hence, we mutated Lys135/Lys136 to Gly135/Gly136 to prevent release of UK. This engineered UK-antibody fusion, AMU1114, significantly decreased the reduction of plasma plasminogen levels in vivo relative to UK. In a photochemically induced mouse model of thrombus, the vascular patency rate was 0% (0/10) in the control, 50% (5/10) in the tPA treatment group, and 90% (9/10) in the AMU1114 treatment group. Although no death was observed 1 hour after administration of each thrombolytic agent, some mice died within 24 hours in all treatment groups, including control. These data indicate the need for further basic studies of AMU1114.

Keywords
► thrombolytic agent
► urokinase
► anti-insoluble fibrin antibody
► engineered
UK-antibody fusion protein

Introduction

Hypercoagulation occurs not only in cardiovascular diseases, but also in cancer and severe infectious diseases such as influenza and coronavirus infection, worsening their pathologies.1–3 In patients with such severe conditions, administration of thrombolytic agents should be performed with caution, and safer forms of administration are desirable. Currently, tissue plasminogen activator (tPA) is the thrombolytic agent used most commonly in clinics around the world because it binds insoluble fibrin (IF) more specifically than urokinase (UK).4 However, even under tPA treatment, bleeding is a clinically serious side effect.5 To address this issue, efforts have been made to increase the fibrinolytic activity of plasminogen activators by selectively targeting them to IF in lesions. For these purposes, a monoclonal
Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-IF Antibody and Mutated UK  
Hanaoka et al.

antibody (mAb) against IF called 59D8 is utilized as a delivery tool. For example, some groups prepared a chemical conjugate of pro-UK with this mAb. Another group produced a recombinant fusion protein of the catalytic domain of UK and 59D8. Still other groups developed chemical conjugates of tPA and 59D8.

However, for several reasons including low yield, inconsistent coupling, and low superiority relative to the original plasminogen activators, none of the fusions or conjugates were evaluated clinically. In addition to technical problems related to chemical conjugation and protein fusion, the 59D8 mAb used in those groups bound not only IF but also fibrinogen, which circulates in the blood. Therefore, it is assumed that those formulations were not efficiently delivered to the lesion because they were neutralized by the large amounts of fibrinogen in the blood.

As part of our research into cancer and blood coagulation, we established a mAb (102–10) that recognizes only IF and not fibrinogen, soluble fibrin (fibrin monomer), or soluble fibrin degradation products (FDPs). We also demonstrated that our anti-IF mAb recognizes an epitope inside a unique pit that is uncovered only when a fibrin clot forms. The epitope in the pit is a hydrophobic region on the β-chain that interacts closely with a region on the γ-chain in a soluble state. Accordingly, anti-IF mAb does not react with fibrinogen, soluble fibrin, or FDP. The amino acid sequence of this epitope is widely conserved among animals ranging from fish to humans. In other words, even though 102–10 is an anti-human IF antibody produced in mice, it also recognizes mouse IF. This suggests that data from mouse experiments can be extrapolated to humans.

Even single-chain tPA (pro-tPA) has enzymatic activity that converts plasminogen in circulating blood into plasmin. Plasmin and activated tPA in the blood are inhibited by innate α2-plasmin inhibitor (α2-PI) and plasminogen activator inhibitor-1 (PAI-1), respectively. On the other hand, pro-UK is rarely activated naturally in blood circulation and is not inhibited by PAI-1. Consequently, UK is active only on IF in the lesion, where plasmin is abundant. Based on these observations, we hypothesized that a thrombolytic agent superior to tPA could be obtained if it were possible to efficiently deliver pro-UK to IF. Thus, we have prepared a fusion protein of pro-UK and anti-IF mAb to deliver pro-UK selectively to IF in lesions in the body.

Methods

Development of mAb 1101 and Its Humanization
The plasminogen β-chain D domain (a.a. 228–491, UniprotKB entry number P02675) was expressed in Escherichia coli and used as an immunogen. The antigen, mixed with adjuvant, was administered four times intraperitoneally to BALB/c mice, followed by final immunization through the tail vein. Three days after the final immunization, the spleen was removed, and the spleen cells were fused with X63 myeloma cells by the PEG method to obtain an antibody-producing hybridoma.

Hybridomas that were immunogen-positive, IF-positive, and fibrinogen-negative were screened by enzyme-linked immunosorbent assay (ELISA). The clone producing an antibody with the highest binding strength and specificity was established and named 1101. The isotype of the antibody was determined using an isotype-specific anti-mouse antibody (Bethyl). An antibody that was unreactive to both IF and fibrinogen was used as a negative control. Cloning was performed by 5′-RACE, and the gene sequence was confirmed. The confirmed complementarity-determining region was inserted into human immunoglobulin G (IgG).

Humanized 1101 and control antibodies were expressed in Chinese hamster ovary (CHO) cells, and IF specificity was confirmed by ELISA.

Enzyme-Linked Immunosorbent Assay

Preparation of IF-Immobilized Plates
Fibrinogen (100 μL of a 10 μg/mL solution; Sigma-Aldrich) was dispensed into each well of an IF-immobilized 96-well plate, and the plates were incubated overnight at 4°C. One hundred microliters of 0.05 U/mL thrombin (Sigma-Aldrich), 7 mM L-cysteine, and 1 mM CaCl2 was added to each well, and the plates were incubated at 37°C for 2 hours. After blocking with N102 (Nichiyu) containing 10% sucrose, blocking was performed again with TBS-T (Tris-buffered saline with Tween-20 (TBS-T) containing 1% bovine serum albumin (BSA), yielding IF-immobilized plates.

ELISA
Fibrinogen (Sigma-Aldrich), soluble fibrin (Sekisui Medical), and FDP (Sekisui Medical), were also immobilized on 96-well plates (1 μg/well of each compound). The plate was reacted with antibody solution (1 μg/mL) for 1 hour, washed with TBS-T, reacted with horseradish peroxidase (HRP)-conjugated anti-human IgG-Fc antibody or anti-mouse IgG-Fc antibody (Bethyl) for 1 hour, and washed with TBS-T. After incubation with the TMB (3,3′,5,5′-tetramethylbenzidine) color-developing reagent for 15 minutes, the reaction was stopped by addition of 2 N H2SO4, and absorbance at 450 nm was measured. The antibodies used in this experiment were 1101, the negative control, and the previously established 59D8 mAb, which recognizes the N-terminus of fibrinogen after thrombin cleavage.

Fibrin Gel Turbidity Assay
The turbidity assay was performed as described previously at 37°C in a 96-well plate (Corning) on a SpectraMax Paradigm plate reader (Molecular Devices, Sunnyvale, California, United States). Assays were performed in quadruplicate. Turbidity was monitored once a minute at a 350 nm wavelength and calculated as the mean value (n = 4) in a volume of 100 μL HBS (HEPES [N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid]-buffered saline solution) at pH 7.4.

For fibrin gel formation, 2.0 mg/mL fibrinogen (Sigma-Aldrich), 5 mM CaCl2 (Wako Pure Chemical), 0.01% Tween 80 (Sigma-Aldrich), and 0.5 NIH unit/mL thrombin (Sigma-Aldrich) were added to 10 μg/mL 1101 mAb or 3 U/mL anti-thrombin (SLS Behring K) as antithrombin III (AT III).
For the lysis of the fibrin gel, 2.0 mg/mL fibrinogen (Sigma-Aldrich), 5 mM CaCl₂ (Wako), 0.01% Tween 80 (Sigma-Aldrich), 0.5 NIH unit/mL thrombin (Sigma-Aldrich), 0.2 μM PLG (Enzyme Research Laboratories), and 0.3 nM tPA (Alteplase, Kyowa Hakko Kirin) were added to 10 μg/mL 1101 mAb or a mixture of 0.10 μM o2-PI (Hematologic Technologies) and 2.0 ng/mL PAI-1 (ProSpec), and used as a negative control.

**Immunohistochemistry of Human Thrombus**

Human tissue sample with thrombus was generously provided by Dr. Genichiro Ishii (Pathology Division of National Cancer Center Hospital East). Immunostaining was performed on paraffin-embedded tissue. In brief, 6 μm thick sections were deparaffinized with xylene and rehydrated with decreasing concentrations of ethanol in water. Inhibition of endogenous peroxidases was performed by incubating slides in 3% hydrogen peroxide (Wako) for 20 minutes. Antigen retrieval was achieved by microwaving the slides for 10 minutes in hot (98°C) Tris-HCl buffer (TB) at pH 9.0, followed by 30 minutes of cooling down to room temperature. The sections were then washed with phosphate-buffered saline (PBS) (Wako) for 10 minutes. After blocking with 5% skimmed milk (Rectron Dickinson) at room temperature for 30 minutes, the sections were incubated overnight at 4°C in a humidified chamber with 10μg/mL of HRP-conjugated 1101 IgG antibody. After washing with PBS for 5 minutes, color development was achieved by applying diaminobenzidine tetrahydrochloride (DAB) staining reagent (Dako) for 5 minutes. After washing, the sections were counterstained with hematoxylin (Muto Pure Chemicals), dehydrated through ethanol and xylene, and coverslipped using Mount-Quick mounting medium (DAI-DM-01, Daid).

**Construction of Several Types of Fab-UK**

UK (wild-type) was linked to the Fab region of the H chain of humanized 1101 antibody via a 16-residue linker (GSGGGSSGGGGSSGSS) (construct 1). The UK mutant (Lys135-Lys136 → Gly135-Gly136) was linked to the same Fab region to yield construct 2 (AMU1114). The His8 tag was added to the C-termini of all constructs. Each of the prepared Fab region to yield construct 2 (AMU1114). The His8 tag was added to the C-termini of all constructs. Each of the prepared Fab-UK in CHO was immediately transferred to a 1.5 mL tube and cooled stand at room temperature for 15 minutes. After the plasma coagulated, the fibrin gel plate was centrifuged at 500 × g for 3 minutes.

**Preparation of Fibrin Gel**

Human fibrinogen (Sigma-Aldrich) labeled with fluorescent Alexa Fluor 647 (Thermo Fisher Scientific) was added to human plasma (Kohjin-bio) with 10 mM CaCl₂ (1/100th volume). Plasma mixed with AF647-labeled fibrinogen was dispensed into a 96 well plate at 140 μL per well, and then 20 NIH units/mL thrombin was added at 7.5 μL/well and left to stand at room temperature for 15 minutes. After the plasma coagulated, the fibrin gel plate was centrifuged at 500 × g for 3 minutes.

**Sample Preparation for the Fibrinolytic Assay**

For the fibrinolytic assay of UK, construct 1, and construct 2/AMU1114 (Fig. 2C), UK (Urokinase, Mochida Pharmaceutical), construct 1, and construct 2/AMU1114 were adjusted to 1 μM in PBS. For the fibrinolytic assay of UK, tPA, and AMU1114 (Fig. 3A), the molecular weights of UK (Urokinase, Mochida Pharmaceutical), tPA (Alteplase, Kyowa Hakko Kirin), and AMU1114 are 46, 59, and 96 kDa, respectively. To determine the approximate specific activity of fibrinolysis of those molecules, UK, tPA, and AMU1114 were adjusted to 1, 1, and 2 mg/mL, respectively, in PBS.

**Fibrinolytic Assay Using the Fibrin Gel**

Each adjusted sample was diluted 10-fold with human plasma (Kohjin-bio) and reacted at 37°C for 120 minutes. Each reacted sample was further diluted 10-fold with human plasma. After adding each sample to a fibrin gel plate (150 μL/well), the plate was reacted at 37°C for 1 hour, and Alexa Fluor 647 eluted in the supernatant was measured at Ex647/Em680.

**Effects of UK, tPA, and AMU1114 on Plasma Level of Plasminogen in Mice**

To observe the systemic effect of UK, tPA, and AMU1114 in vivo, these thrombolytic agents were administered intravenously in C57BL/6j mice (female, Japan Charles River) at equal molar ratios; the in vitro fibrinolytic specific activities of the three agents are almost identical. According to previous evaluations of in vitro specific activity of fibrinolysis, UK and tPA were injected intravenously at 10 mg/kg,27 and AMU1114 was administered intravenously at 20 mg/kg. Each group consisted of three mice. Thirty minutes after administration, the mice were anesthetized with isoflurane, and 500 μL of blood was collected from the heart. The blood was immediately transferred to a 1.5 mL tube and cooled with a cooling agent on ice until use. A syringe prefilled with 50 μL of 19% sodium citrate solution was used for blood collection. The collected blood was centrifuged at 10,000 × g for 2 minutes to collect plasma and stored at −80°C until use.

Each frozen plasma sample was thawed on ice and diluted 40-fold with TBS, and 20 μL of the diluted sample was mixed with 100 μL of 250 unit/mL UK. As a control, 20 μL of diluted sample was mixed with 100 μL TBS. The mixed sample was reacted at 37°C for 1 hour, mixed with 20 μL of substrate (Test Team SPLG, Sekisui Medical), and reacted at 37°C for 6 hours. After the reaction, the absorbance at 405/505 was measured. Based on the measured absorbance, the level of plasminogen...
in each sample was calculated based on the level of plasminogen in plasma collected from untreated mice.

**In Vivo Thrombus Formation and Redissolution of Thrombi Formed by Thrombolytic Agents**

This experiment was entrusted to LSI Medience, which has extensive experience in mouse thrombosis research. Briefly, a thrombus was formed in the carotid artery of the mouse by the photochemically induced thrombosis (PIT) method, and each thrombolytic agent was administered to determine when the carotid artery was opened or occluded. In the PIT method, light with a wavelength of 545 nm is used to irradiate Rose Bengal, generating singlet oxygen at the irradiation site that damages endothelial cells and induces platelet aggregation, thereby promoting thrombus formation.28

Ninety microliters of alteplase (tPA) was administered to C57BL/6J mice (male, Charles River Laboratories in Japan) at 3 mg/kg body weight (average body weight, 30 g; \( n = 10 \) for each administration group); AMU1114 was administered at 90 µL at 6 mg/kg. At this dose, tPA and AMU1114 are equally active in vitro systems. In each experiment, thrombus formation in the carotid artery was initiated by administration of Rose Bengal dye at 0 minutes, followed by light irradiation. Five minutes after the start of thrombus formation, PBS, tPA, or AMU1114 was administered. Irradiation was stopped 30 minutes after the start of thrombus formation, and observation was terminated 30 minutes after that. The times when the carotid artery was occluded or open were recorded over the 60 minute observation period. The CRO that conducted this PIT test commented that approximately 10% of the deaths in a normal anesthesia test (30 minute irradiation, 60 minute measurement) can be seen in each test. The cause of death may not be bleeding. After irradiation with green light to form a thrombosis, the mice are awakened from anesthesia and treated with the test substances 1 hour after irradiation. When the mouse was awakened, there was a symptom of turning movement, so the mouse likely died probably due to a thrombus jumping and causing a cerebral infarction.

**Effects of Three Thrombolytic Agents on the Lesion of the Thrombus**

In the PIT model, tPA, UK, and AMU1114 were administered intravenously to mice 1 hour after termination of irradiation. Mice were sacrificed at 1 and 24 hours after the intravenous injection of each thrombolytic agent, and the thrombotic lesion was excised to observe pathological changes, including hemorrhage of the lesion. Each group consisted of two mice.

**Immunostaining of Mouse Thrombus**

Arterial lesions of the PIT-treated mice were obtained and paraffin-embedded. Formalin-fixed paraffin-embedded sections were deparaffinized with xylene and rehydrated with ethanol. After hydrogen peroxidase treatment and antigen retrieval, the sections were blocked with 1% BSA (Sigma-Aldrich) in PBS and stained with 10 µg/mL 1101-HRP conjugated or 5 µg/mL of HRP-conjugated PLAU mAb (OriGene). Antigen retrieval for PLAU mAb was achieved by autoclaving the slides for 3 minutes in hot (120°C) Tris-HCl buffer (TB) at pH 9.0. Other samples were processed under the same conditions as for immunostaining of human thrombus. Hematoxylin/eosin staining was performed according to a general protocol.

**Statistical Analyses**

Statistical analyses of ELISA assay, fibrinolytic assay, and plasma level of plasminogen were performed using the EZR software. \( p \)-Values were determined by analysis of variance and Tukey’s test.

In animal experiments, we compared the control with tPA and control with AMU1114. We also compared tPA and AMU1114 in terms of the number of cases in which blood vessels were patent at the end of the experiment. The time to vascular occlusion and the patency rate of blood vessels were tested by the F-test (significance level: 5%) for uniformity of variance. For the number of cases in which blood vessels were patent at the end of the experiment, Fisher’s exact test was performed. If the variances were uniform, Student’s \( t \)-test was used for comparison. If the variances were not uniform, the comparison was performed using the Aspin–Welch \( t \)-test. Significance levels were set to 5 and 1%, and a two-sided test was performed. For the evaluation data, the average value ± standard error of each group was obtained. In addition, individuals whose blood vessels were patent at the end of the experiment were counted.

**Results**

**Characterization of an Anti-IF mAb**

The anti-IF mAb clone 1101 was established by immunizing mice with the D domain of fibrinogen \( \beta \)-chain (a.a. 228–491) and subsequently humanized24 (\Fig. 1A). 1101 bound only IF and not soluble fibrinogen, the fibrin monomer, or FDP. On the other hand, mAb 9D8, which recognizes the N-terminus of fibrinogen cleaved by thrombin, recognized not only IF but also fibrinogen (\Fig. 1B).5 Like 102–10, 1101 bound not only human IF but also mouse IF (\Fig. 1C).17 In addition, the binding strength and specificity of 1101 for IF was higher than that of 102–10 (data not shown). Immunohistochemistry with 1101 revealed clear IF deposition in human thrombus (\Fig. 1D). In the IF formation assay, AT III suppressed IF formation. On the other hand, 1101 caused IF formation to the same extent as control PBS. In the fibrinolysis assay system, \( \alpha_2 \)-PI and PAI-1 clearly decreased fibrinolytic activity. As in the control, 1101 did not delay fibrinolysis. These results indicated that the coagulation and fibrinolytic systems were unaffected by 1101, as with the previously established antibody 102–10 (\Fig. 1E).26

**Comparison of UK and Its Constructs**

A portion of UK was linked to the Fab region of the H chain of humanized antibody 1101 via a 16-residue linker. An antibody–UK fusion protein was generated for two types of UK (\Fig. 2A). Construct 1 is a fusion protein of antibody
and wild-type UK. Construct 2 (AMU1114) is a fusion protein of antibody and mutated UK with the Gly135/Gly136 substitutions. UK contains two sites cleaved by plasmin; one of them, Lys158/Ile159, is in the UK catalytic domain. Cleavage of this site causes activation of UK, but even if it is cleaved, active UK does not separate from the fusion protein because it is connected by an S-S bond that sandwiches the cleavage site. The other plasmin cleavage site is Lys135/Lys136, which is located on the N-terminal end of the UK catalytic domain, called the Kringle domain. Because this cleavage site is not connected by an S-S bond, cleavage by plasmin results in release of activated UK from construct 1, which would result in insufficient IF lysis.

Therefore, by converting Lys135/Lys136 to Gly135/Gly136, we prevented this region of AMU1114 from being cleaved by plasmin, enabling activation of UK in the fusion protein. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis clearly indicated a 96-kDa AMU1114 in the nonreduced condition. In the reduced condition, the 72.7-kDa heavy chain of 1101 Fab connected to the mutated UK and the 23.4-kDa light chain of 1101 Fab were obtained (Fig. 2B). The mutated UK did not decrease fibrinolytic activity; the in vitro fibrinolytic activity of AMU1114 was similar to that of UK and construct 1 (Fig. 2C).

Fibrinolytic Activity In Vitro and In Vivo
When comparable molar quantities of UK, tPA, and AMU1114 were applied to fibrin gels, all three exerted similar fibrinolytic activities (Fig. 3A).

Plasma plasminogen levels after administration of PBS, UK, tPA, and AMU1114 were 94.7, 51.1, 74.9, and 85.5%, respectively, relative to the level in plasma of untreated mice. UK administration significantly decreased plasma plasminogen relative to the other groups (UK vs. tPA, p < 0.05 and UK vs. AMU1114, p < 0.01). There was no significant difference in plasminogen levels between tPA and AMU1114 treatment. However, plasma plasminogen was significantly lower in the tPA group than in the untreated group (p < 0.01), and there was no significant difference between the AMU1114 and untreated groups (Fig. 3B).

Comparison of Antithrombotic Activities
In the PIT experiment in the mouse carotid artery, the times from the start of green light irradiation to complete obstruction of blood flow in the control, tPA, and AMU1114 groups were 553 ± 142, 1,136 ± 308, and 1,268 ± 308 seconds, respectively. Multiple comparisons were performed among the three groups, but no significant differences were detected (Fig. 4A).

Rates of vascular patency for 60 minutes were 21.1 ± 3.7, 50.9 ± 10.1, and 66.3 ± 7.2%, respectively, in the control, tPA, and AMU1114 groups. The rate of vascular patency after 60 minutes was significantly higher in the tPA and AMU1114 treatment groups than in the control group (Fig. 4B). In addition, when multiple comparisons were performed among the control, tPA, and AMU1114 groups, significant differences were detected between the control and tPA group.
and between the control and AMU1114 group ($p < 0.05$) and between the tPA and AMU1114 groups, although AMU1114 tended to have a higher rate of vascular patency than tPA. At the end of the measurement, the number of mice with open blood vessels was 0/10 in the control group, 5/10 in the tPA group, and 9/10 in the AMU1114 group (Fig. 5A, B). Significant differences in the number of individuals whose blood vessels
were patent were detected between the control and tPA groups ($p = 0.00325$), and between the control and AMU1114 groups ($p = 0.000119$). On the other hand, no significant difference was detected between the tPA and AMU1114 groups, although AMU1114 tended to have a stronger thrombolytic effect than tPA ($p = 0.141$).

**Effects of Three Thrombolytic Agents on the Thrombotic Lesion**

In this experiment, there were no deaths in any group 1 hour after the intravenous administration of each thrombolytic agent; however, deaths were confirmed in one of two cases each in the control, UK, and tPA groups at 24 hours after the completion of the experiment. The results of this study suggest that AMU1114 is a highly effective thrombolytic agent compared to the other two agents.
administration. On the other hand, in the AMU group, death was confirmed in two of two cases. Three mice died before administration of thrombolytic agents.

No change in the wall of the carotid artery was observed in any group (Fig. 6). AMU1114 delivered UK more efficiently and selectively to the IF in the lesion than UK alone (Fig. 6).

Discussion

In this study, we successfully constructed a fusion protein of mutated UK and anti-IF mAb, AMU1114, and confirmed that it retained the activity of UK. The in vitro fibrinolytic activity of AMU1114 was almost the same as that of tPA. According to the in vivo experiments of the effect of test substances on plasminogen consumption in blood of normal mice, the systemic effect of AMU1114 may be lower than that of UK. No deaths were observed at the time of administration of each thrombolytic substance in any group of normal mice. However, to proceed with clinical development, detailed pathological evaluation of the thrombus site following the administration of AMU1114 is necessary. In terms of the antithrombotic effect of test substances, there was no significant difference in the time from the start of green light irradiation until complete occlusion of blood flow (TTO) among the control, tPA, and AMU1114 groups, although tPA and AMU1114 took longer than the control. Regarding vascular patency, tPA and AMU1114 had longer vascular patency times during blood flow measurements than the control. At the end of blood flow measurement, the number of individuals whose blood vessels were patent was 0/10 for controls, 5/10 for tPA, and 9/10 for AMU1114. Thus, tPA and AMU1114 had the effect of thawing the prepared thrombus and reopening blood vessels. At the same time, AMU1114 had a greater thrombolytic effect than tPA, as reflected by the larger number of individuals with reopened blood vessels. We will have to confirm these data with another set of in vivo experiments. Moreover, these observations should be confirmed in comparison with enzymes such as tenecteplase and desmoteplase, which have recently been clinically tested.

Our fusion protein has three main characteristics: first, because AMU1114 recognizes only IF, the mAb can be delivered to IF exclusively at lesion sites in vivo without being neutralized by precursors or degradation products in blood. Although the strategy for delivering plasminogen activators to the affected area with an antibody against anti-IF has been considered, our previous and present experiments confirmed that the antibody, 59D8, binds to both IF and fibrinogen (Fig. 1B). In other words, the 59D8 antibody is neutralized by fibrinogen, which is much more abundant than IF in vivo, and may not be effectively delivered to the lesion. On the other hand, the antibody we have established, 1101, enables selective in vivo delivery by recognizing only IF; this is possible because the epitope of 1101 exists on the β-chain in the pit structure that is only present in IF. Second, AMU1114 acts selectively on IF in lesions. The plasminogen activator selectively converts plasminogen into active plasmin on IF.29 Plasmin is inactivated in vivo by endogenous inhibitors such as α2-PI, except when IF is
potentially fatal coagulopathy associated with cerebral infection and cancer. Although it may be difficult to use a thrombolytic agent in such situations, we believe that developing a safer formulation is a step in the right direction.

Although no deaths could be confirmed in any group 1 hour after administration of the test substances in the mouse thrombus model, one mouse died after administration of control, UK, and tPA, and two of two mice that received AMU1114 died by 24 hours. No hemorrhagic lesions were found locally in the thrombus in any group after administration of any thrombolytic agent. Thus far, the cause of death has not been identified. In this PIT experimental model, approximately 10% of mice die following thrombus formation. In any case, it is important to determine the cause of death, and it may be necessary to consider changing the model of thrombus formation. We should carefully identify the disease or thrombosis to which AMU1114 could be applied in the future.

Thrombotic complications occur in patients with various infectious diseases and cancer. They may also be associated with worsening of clinical condition, for example, fibrosis associated with elevated blood coagulation at local sites of infection and cancer. Although it may be difficult to use a thrombolytic agent in such situations, we believe that developing a safer formulation is a step in the right direction.

While additional data are accumulated, a research cell bank of this antibody-UK fusion protein should be established for the purpose of future clinical trials in patients with potentially fatal coagulopathy associated with cerebral infarction, myocardial infarction, cancers, and viral infection.

What is known about this topic?
• Currently, tissue plasminogen activator (tPA) is used clinically because it has higher binding specificity for insoluble fibrin (IF).
• Even pro-tPA has catalytic activity against substrates other than IF, and it also has the side effect of bleeding.
• Urokinase (UK) is specifically activated on IF but only binds IF weakly.

What does this paper add?
• The antibody that we established recognizes a pit structure formed only in IF and therefore never binds to fibrinogen.
• We generated a novel potent thrombolytic fusion protein consisting of our anti-IF antibody and mutated UK.
• In a mouse thrombus formation experiment, our fusion protein had a greater thrombolytic effect than tPA.

Author Contributions
Y.M. developed the original concept for the study. S.H. and Y.M. designed the experiments. S.S. and Y.M. conducted pharmacological studies, immunohistochemistry, and turbidity assays. S.H. and Y.M. discussed and wrote the manuscript. All authors reviewed and contributed to the final version of manuscript.

Funding
This work was financially supported in part by National Cancer Center Research and Development Fund (26-A-14 and 29-A-9 to Y.M.); the Project for Cancer Research and Therapeutic Evolution from the Japan Agency for Medical Research and Development (AMED) (17cm0106415h0002 to Y.M.); the Takeda Science Foundation (to Y.M.); and the Kobayashi Foundation for Cancer Research (to Y.M.).

Conflict of Interest
Y.M. is co-founder, shareholder, and Board Member of RIN Institute, Inc., a venture company spun out from the National Cancer Center, Japan. S.H. and S.S. are employees of RIN Institute, Inc.

Acknowledgment
We thank Dr. Osman for technical support and Dr. Genichiro Ishii for advice on pathology.

References
1 Matsumura Y. Cancer and blood coagulation. In: Matsumura Y, Tarin D, eds. Cancer Drug Delivery Systems Based on the Tumour Microenvironment. Tokyo: Springer; 2020:23–40
2 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506
3 Goeijenbier M, van Wissen M, van de Weg C, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012;84(10):1680–1696
4 Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2(8606):293–298
5 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581–1587
6 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin–like peptide bind to human fibrin but not fibrinogen. Science 1983;222(4628):1129–1132
7 Dewerchin M, Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies. Bioconjug Chem 1991;2(05):293–300
8 Bode C, Runge MS, Newell JB, Matsueda GR, Haber E. Thrombolysis by a fibrin-specific antibody Fab’–urokinase conjugate. J Mol Cell Cardiol 1987;19(04):335–341
9 Bode C, Runge MS, Schönermark S, et al. Conjugation to antifibrin Fab’ enhances fibrinolytic potency of single–chain urokinase plasminogen activator. Circulation 1990;81(06):1974–1980
10 Hagemeyer CE, Tomic I, Weirich U, et al. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost 2004;2(05):797–803
11 Runge MS, Quertermous T, Zavodny Pj, et al. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. J Thromb Haemost 2004;2(05):797–803
12 Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci U S A 1987;84(21):7659–7662
13 Runge MS, Harker LA, Bode C, et al. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996;94(06):1412–1422
14 Runge MS, Bode C, Haber E, Quertermous T. Hybrid molecules: insights into plasminogen activator function. Mol Biol Med 1991; 8(02):245–255
15 Runge MS, Bode C, Matsueda GR, Haber E. Conjugation to an anti-fibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 1988;27 (04):1153–1157
16 Yasunaga M, Manabe S, Matsumura Y. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 2011;102(07):1396–1402
17 Hisada Y, Yasunaga M, Hanaoka S, et al. Discovery of an uncovered region in fibrin clots and its clinical significance. Sci Rep 2013; 3:2604
18 Boose JA, Kuismanen E, Gerard R, Sambrook J, Gething MJ. The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site. Biochemistry 1989;28(02):635–643
19 Rånby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 1982;27(02):175–183
20 Moroi M, Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976;251(19): 5956–5965
21 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986;83(18):6776–6780
22 Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest 1989;84(02):647–655
23 Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986;261(17):7644–7651
24 Kuramochi T, Igawa T, Tsuchida H, Hattori K. Humanization and simultaneous optimization of monoclonal antibody. Methods Mol Biol 2014;1060:123–137
25 Kim PY, Stewart RJ, Lipson SM, Nesheim ME. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost 2007;5(06):1250–1256
26 Obonai T, Fuchigami H, Furuya F, Kozuka N, Yasunaga M, Matsumura Y. Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. Sci Rep 2016;6:23613
27 Tobe A, Narimatsu A, Haru A, et al. General pharmacological studies of GMK-527(rt-PA). Jpn Pharmacol Ther 1988;25:195–221
28 Mizuno M, Ito Y, Sugidachi A. A novel porcine model of thrombotic myocardial infarction with cardiac dysfunction sensitive to dual antiplatelet therapy. Eur J Pharmacol 2018;834:103–108
29 Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 138(01):277–280